Zenas BioPharma, Inc. (ZBIO) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ZBIO currently has 41.9M outstanding shares. with moderate dilution risk from 13.5M authorized shares representing 32.3% potential dilution. The company has minimally diluted shareholders by 9.24% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 31, 2026 |
8-K filing: Zenas BioPharma, Inc. completed a public offering of $200 million aggregate principal amount of 2.50% Convertible Senior Notes due 2032 and an equity offering of 5,000,000 shares of common stock at a price of $20.00 per share. ($100.0M proceeds) |
42M | 14M |
| Oct 08, 2025 |
8-K filing: Zenas BioPharma, Inc. issued 5,000,000 shares of common stock to InnoCare Pharma Inc. as part of a License Agreement and will issue an additional 2,000,000 shares upon achieving a milestone. Additionally, Zenas will sell 6,310,811 shares of common stock to Institutional, Director, and Officer Investors in a private placement. ($120.0M proceeds) |
42M | 14M |
| Aug 12, 2025 |
10-Q filing | 41.9M shares outstanding |
42M | 14M |
| May 15, 2025 |
10-Q filing | 41.8M shares outstanding |
42M | 14M |
| Mar 11, 2025 |
10-K filing | 41.8M shares outstanding |
42M | 14M |
| Nov 12, 2024 |
10-Q filing | 41.8M shares outstanding |
42M | 14M |
| Sep 06, 2024 |
S-1/A filing: This S-1/A filing registers the offering of common stock with an underwriter's over-allotment option, detailing the use of proceeds for clinical development and commercial launch preparations, while also providing information on expenses, indemnification, and financial data. |
38M | 14M |
| Aug 22, 2024 |
S-1 filing: This is an S-1 filing for a common stock offering, with Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities acting as underwriters. |
230M | 0 |